{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:30:48Z","timestamp":1791862248552,"version":"4.3.4"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"7","funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>This study examined how people interpret overall survival (OS), overall response rate (ORR), and progression-free survival (PFS) endpoints in the context of direct-to-consumer television ads. Although there is little research on this topic, initial evidence suggests that people can misinterpret these endpoints. We hypothesized that understanding of ORR and PFS would be improved by adding a disclosure (\u201cWe currently do not know if [Drug] helps patients live longer\u201d) to ORR and PFS claims.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted 2 online studies with US adults examining television ads for fictional prescription drugs indicated to treat lung cancer (N\u2005=\u2005385) or multiple myeloma (N\u2005=\u2005406). The ads included claims about OS, ORR with and without a disclosure, or PFS with and without a disclosure. In each experiment, we randomized participants to view 1 of 5 versions of a television ad. After viewing the ad twice, participants completed a questionnaire that measured understanding, perceptions, and other outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In both studies, participants correctly differentiated between OS, ORR, and PFS via open-ended responses; however, participants in the PFS conditions (versus ORR conditions) were more likely to make incorrect inferences about OS. Supporting the hypothesis, adding a disclosure made expectations around living longer and quality-of-life improvements more accurate.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Disclosures could help reduce the extent to which people misinterpret endpoints like ORR and PFS. More research is needed to establish best-practice recommendations for using disclosures to improve patient understanding of drug efficacy without changing their perception of the drug in unintended ways.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyad064","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T17:50:38Z","timestamp":1682013038000},"page":"e542-e553","source":"Crossref","is-referenced-by-count":12,"title":["Patient Understanding of Oncology Clinical Trial Endpoints in Direct-to-Consumer Television Advertising"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7621-7554","authenticated-orcid":false,"given":"Helen W","family":"Sullivan","sequence":"first","affiliation":[{"name":"Office or Prescription Drug Promotion, US Food and Drug Administration , Silver Spring, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amie C","family":"O\u2019Donoghue","sequence":"additional","affiliation":[{"name":"Office or Prescription Drug Promotion, US Food and Drug Administration , Silver Spring, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1777-290X","authenticated-orcid":false,"given":"Vanessa","family":"Boudewyns","sequence":"additional","affiliation":[{"name":"Center for Communication & Media Impact, RTI International, Research Triangle Park , NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0947-7409","authenticated-orcid":false,"given":"Ryan S","family":"Paquin","sequence":"additional","affiliation":[{"name":"Center for Communication & Media Impact, RTI International, Research Triangle Park , NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Ferriola-Bruckenstein","sequence":"additional","affiliation":[{"name":"Center for Communication & Engagement Research, RTI International , Research Triangle Park, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"issue":"8","key":"2023070520012923100_CIT0001","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/cncr.32730","article-title":"Patient familiarity with, understanding of, and preferences for clinical trial endpoints and terminology","volume":"126","author":"von Itzstein","year":"2020","journal-title":"Cancer."},{"issue":"2","key":"2023070520012923100_CIT0002","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s13187-016-1107-1","article-title":"Quantitative information on oncology prescription drug websites","volume":"33","author":"Sullivan","year":"2018","journal-title":"J Cancer Educ."},{"key":"2023070520012923100_CIT0003","author":"McCaffrey","year":"2017"},{"key":"2023070520012923100_CIT0004","author":"iSpot.tv","year":"2022"},{"key":"2023070520012923100_CIT0005","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1200\/JOP.2011.000513","article-title":"Update on direct-to-consumer marketing in oncology","volume":"8","author":"Gray","year":"2012","journal-title":"J Oncol Pract"},{"key":"2023070520012923100_CIT0006","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/nrc2999","article-title":"Cancer-related direct-to-consumer advertising: a critical review","volume":"11","author":"Kontos","year":"2011","journal-title":"Nat Rev Cancer."},{"key":"2023070520012923100_CIT0007","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1001\/jamaoncol.2016.2463","article-title":"Direct-to-consumer drug advertising in oncology is not beneficial to patients or public health","volume":"2","author":"Schnipper","year":"2016","journal-title":"JAMA Oncol"},{"issue":"8","key":"2023070520012923100_CIT0008","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/MLR.0000000000000752","article-title":"Effect of &#x2028;direct-to-consumer advertising on statin use in the United States","volume":"55","author":"Chang","year":"2017","journal-title":"Med Care."},{"key":"2023070520012923100_CIT0009","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1164\/rccm.201409-1585OC","article-title":"Effect of direct-to-consumer advertising on asthma medication sales and healthcare use","volume":"192","author":"Daubresse","year":"2015","journal-title":"Am J Respir Crit Care Med."},{"key":"2023070520012923100_CIT0010","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1007\/s11606-020-06218-x","article-title":"Direct-to-consumer drug advertisement and prescribing practices: evidence review and practical guidance for clinicians","volume":"36","author":"Franquiz","year":"2021","journal-title":"J Gen Intern Med."},{"key":"2023070520012923100_CIT0011","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/ntr\/ntv198","article-title":"Effects of televised direct-to-&#x2028;consumer advertising for varenicline on prescription dispensing in the United States, 2006-2009","volume":"18","author":"Kim","year":"2016","journal-title":"Nicotine Tob Res."},{"key":"2023070520012923100_CIT0012","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/jama.2016.21041","article-title":"Association between direct-to-consumer advertising and testosterone testing and initiation in the United States, 2009-2013","volume":"317","author":"Layton","year":"2017","journal-title":"JAMA."},{"key":"2023070520012923100_CIT0013","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1007\/s11606-013-2379-3","article-title":"Direct-to-consumer television advertising exposure, diagnosis with high cholesterol, and statin use","volume":"28","author":"Niederdeppe","year":"2013","journal-title":"J Gen Intern Med."},{"key":"2023070520012923100_CIT0014","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s11606-014-3063-y","article-title":"The effect of competing direct-to-consumer advertising campaigns on the use of drugs for benign prostatic hyperplasia: time series analysis","volume":"30","author":"Skeldon","year":"2015","journal-title":"J Gen Intern Med."},{"key":"2023070520012923100_CIT0015","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1200\/JCO.2008.20.6599","article-title":"Cancer-related direct-to-consumer advertising: awareness, perceptions, and reported impact among patients undergoing active cancer treatment","volume":"27","author":"Abel","year":"2009","journal-title":"J Clin Oncol."},{"key":"2023070520012923100_CIT0016","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/cncr.27814","article-title":"Impact of oncology-related direct-to-consumer advertising: association with appropriate and inappropriate prescriptions","volume":"119","author":"Abel","year":"2013","journal-title":"Cancer."},{"key":"2023070520012923100_CIT0017","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s41391-020-0234-2","article-title":"Exposure to direct-&#x2028;to-consumer advertising is associated with overestimation of benefits regarding ultrahypofractionated radiation therapy for prostate cancer","volume":"23","author":"Caputo","year":"2020","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"11","key":"2023070520012923100_CIT0018","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/jamaoncol.2022.3769","article-title":"Misinterpretation of Surgeons\u2019 statements on cancer removal\u2014the adverse effects of \u201cWe Got It All\u201d.","volume":"8","author":"Wong","year":"2022","journal-title":"JAMA Oncol"},{"issue":"6","key":"2023070520012923100_CIT0019","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jamaoncol.2017.5618","article-title":"A 25-year experience of US Food and Drug Administration accelerated approval of malignant hematology and oncology drugs and biologics: a review","volume":"4","author":"Beaver","year":"2018","journal-title":"JAMA Oncol"},{"issue":"10","key":"2023070520012923100_CIT0020","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1007\/s11606-020-06028-1","article-title":"Evaluation of selective outcome reporting bias in efficacy endpoints in print and television advertisements for oncology drugs","volume":"35","author":"Wayant","year":"2020","journal-title":"J Gen Intern Med."},{"issue":"8","key":"2023070520012923100_CIT0021","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1634\/theoncologist.2018-0761","article-title":"Patient-friendly language to facilitate treatment choice for patients with cancer","volume":"24","author":"Kim","year":"2019","journal-title":"Oncologist"},{"issue":"11","key":"2023070520012923100_CIT0022","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41416-021-01495-7","article-title":"An urgent call to raise the bar in oncology","volume":"125","author":"Schnog","year":"2021","journal-title":"Br J Cancer."},{"issue":"9","key":"2023070520012923100_CIT0023","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.pec.2020.03.018","article-title":"Patients\u2019 understanding of oncology clinical endpoints: a literature review","volume":"103","author":"Boudewyns","year":"2020","journal-title":"Patient Educ Couns."},{"issue":"12","key":"2023070520012923100_CIT0024","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1001\/jamaoncol.2019.3338","article-title":"The value of progression-&#x2028;free survival as a treatment end point among patients with advanced cancer: a systematic review and qualitative assessment of the literature","volume":"5","author":"Raphael","year":"2019","journal-title":"JAMA Oncol"},{"issue":"12","key":"2023070520012923100_CIT0025","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1634\/theoncologist.2020-0402","article-title":"Patients\u2019 understanding of oncology clinical endpoints: environmental scan and focus groups","volume":"25","author":"Sullivan","year":"2020","journal-title":"Oncologist"},{"key":"2023070520012923100_CIT0026","doi-asserted-by":"crossref","first-page":"509","DOI":"10.6061\/clinics\/2014(08)02","article-title":"Treatment priorities in oncology: do we want to live longer or better?","volume":"69","author":"Marta","year":"2014","journal-title":"Clinics"},{"issue":"21","key":"2023070520012923100_CIT0027","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2005.03.6236","article-title":"Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer","volume":"24","author":"Matsuyama","year":"2006","journal-title":"J Clin Oncol."},{"issue":"16","key":"2023070520012923100_CIT0028","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1001\/archinternmed.2011.396","article-title":"Communicating uncertainties about prescription drugs to the public: a national randomized trial","volume":"171","author":"Schwartz","year":"2011","journal-title":"Arch Intern Med."},{"key":"2023070520012923100_CIT0029","doi-asserted-by":"crossref","first-page":"747","DOI":"10.15171\/ijhpm.2015.151","article-title":"Health literacy impact on national healthcare utilization and expenditure","volume":"4","author":"Rasu","year":"2015","journal-title":"Int J Health Policy Manag"},{"key":"2023070520012923100_CIT0030","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s11606-008-0520-5","article-title":"Validation of screening questions for limited health literacy in a large VA outpatient population","volume":"23","author":"Chew","year":"2008","journal-title":"J Gen Intern Med."},{"key":"2023070520012923100_CIT0031","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/j.1525-1497.2006.00532.x","article-title":"Brief report: screening items to identify patients with limited health literacy skills","volume":"21","author":"Wallace","year":"2006","journal-title":"J Gen Intern Med."},{"issue":"2","key":"2023070520012923100_CIT0032","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1377\/hlthaff.19.2.110","article-title":"Direct-to-consumer prescription drug advertising: trends, impact, and implications","volume":"19","author":"Wilkes","year":"2000","journal-title":"Health Aff."},{"issue":"2","key":"2023070520012923100_CIT0033","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/pds.4914","article-title":"Consumer understanding of the scope of FDA\u2019s prescription drug regulatory oversight: a nationally representative survey","volume":"29","author":"Sullivan","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"10","key":"2023070520012923100_CIT0034","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.sapharm.2017.07.015","article-title":"Serious and actionable risks, plus disclosure: investigating an alternative approach for presenting risk information in prescription drug television advertisements","volume":"14","author":"Betts","year":"2018","journal-title":"Res Social Adm Pharm."},{"issue":"12","key":"2023070520012923100_CIT0035","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/onco.13972","article-title":"Physician interpretation of data of uncertain clinical utility in oncology prescription drug promotion","volume":"26","author":"Boudewyns","year":"2021","journal-title":"The Oncologist"},{"key":"2023070520012923100_CIT0036","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00520-016-3408-7","article-title":"Therapeutic aims of drugs offering only progression-free survival are misunderstood by patients, and oncologists may be overly optimistic about likely benefits","volume":"25","author":"Fallowfield","year":"2017","journal-title":"Support Care Cancer."},{"issue":"3","key":"2023070520012923100_CIT0037","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/joca.12227","article-title":"Consumer reactions to price comparison and disclosure information in prescription drug print advertising","volume":"53","author":"Aikin","year":"2019","journal-title":"J Cons Aff."},{"issue":"3","key":"2023070520012923100_CIT0038","first-page":"195","article-title":"Physician response to &#x2028;contextualized price-comparison claims in prescription drug advertising","volume":"10","author":"Betts","year":"2017","journal-title":"J Commun Healthc"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/7\/e542\/50825972\/oyad064.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/7\/e542\/50825972\/oyad064.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T20:02:12Z","timestamp":1688587332000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/7\/e542\/7133647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":38,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,4,20]]},"published-print":{"date-parts":[[2023,7,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad064","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7,1]]},"published":{"date-parts":[[2023,4,20]]}}}